In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over,

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super Bowl ad, leveling the accusation against brand-name weight loss drugs. Set to the tune of Childish Gambino’s “This Is America,

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity treatments continue to improve.

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA Psychiatry, researchers report that semaglutide, better known as Ozempic or Wegovy, helped people with alcohol addiction reduce their craving and drink less.

All doses of Novo's diabetes treatment Ozempic and weight-loss drug Wegovy were listed as available on the FDA's website in October, but the treatments were not taken off the offi

A bipartisan group of U.S. state and territory attorneys general is pressing the FDA to take prompt action against those threatening public health by marketing counterfeit forms of branded weight loss medications developed by Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY).